Passion for Health
삼성바이오에피스는 더 많은 환자들에게 고품질의 바이오의약품을 합리적인 가격으로 사용할 수 있는 기회를 제공하기 위해 최선을 다하고 있습니다.
News & Stories
삼성바이오에피스의 최신 소식과 이야기를 만나보세요.
NEWS
Jun 12, 2025
Jun 9, 2025
Jun 4, 2025
May 30, 2025
The new ICH guideline streamlines the biosimilar development process. Samsung Bioepis will continue to support the IGBA and ICH and their efforts to improve the...
Jun 26, 2025
Biosimilars are reshaping the biopharma industry by accelerating innovation. At Samsung Bioepis, we challenge traditional approaches and embrace new technologie...
Jun 24, 2025
At ACCESS US 25, Gillian Woollett highlighted streamlined development for biosimilars as essential for improving complex traditional models, reducing time and c...
Jun 23, 2025
Today in Biosimilars: On June 20, 2024, the FDA proposed new guidance removing the need for switching studies to demonstrate interchangeability—marking a major ...
Jun 20, 2025
Myth: Interchangeable biosimilars are safer and more effective. Fact: Interchangeability is a US regulatory term—not a measure of clinical superiority.
Jun 18, 2025
@EHA_Hematology Congress 2025, Samsung Bioepis reiterated its commitment to shaping the future of advanced therapeutic options in hematology.
Jun 16, 2025
LINKEDIN
The new guideline by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is another milestone step tow...
At ACCESS US 25, Gillian Woollett shared key insights on the need for a more efficient and sustainable biosimilar development model. Biosimilars offer significa...
At the European Hematology Association (EHA) Congress 2025, Samsung Bioepis reiterated its commitment to shaping the future of advanced therapeutic options in h...
Join Us
삼성바이오에피스는 미래를 이끌어갈 인재를 기다리고 있습니다.
오늘 하루 그만보기 닫기
삼성바이오에피스 홈페이지에서 당사 소셜미디어 사이트로 이동하시겠습니까?